Stock listing
NASDAQ:PLRZ Polyrizon Ltd. Stock
Home listing (NASDAQ) of Polyrizon Ltd.
Follow Polyrizon Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:PLRZ
$9.31 USD -1.72 (-15.6%)
Close on Nov 20, 2026
- Day range
- $9.26 – $9.90 USDNov 20, 2026
- Volume
- 4,850 sharesNov 20, 2026
- Market cap
- $22.61M USDAt the close on Nov 20, 2026 · price × 2.43M shares outstanding
- 52-week range
- $2.88 – $18.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $451,841 USDMedian day 17,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PLRZ · Home | $9.31 USD | -1.72 (-15.6%) | 4,850 | $9.897 | $9.897 | $9.26 | $11.03 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PLRZ · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $9.31 | -1.72 | -15.6% | $9.897 | $9.897 | $9.26 | 4,850 | |
| $11.03 | +0.38 | +3.6% | $10.44 | $11.29 | $10.00 | 12,347 | |
| $10.65 | -0.05 | -0.5% | $11.01 | $11.01 | $10.40 | 15,656 | |
| $10.70 | -0.35 | -3.2% | $10.50 | $10.99 | $10.29 | 4,330 | |
| $11.05 | -0.43 | -3.7% | $10.75 | $11.05 | $10.75 | 5,712 | |
| $11.48 | +0.463 | +4.2% | $10.65 | $11.48 | $10.00 | 19,720 | |
| $11.02 | +0.087 | +0.8% | $10.93 | $11.22 | $10.50 | 8,077 | |
| $10.93 | -0.12 | -1.1% | $10.82 | $11.12 | $10.57 | 3,819 | |
| $11.05 | +0.005 | 0.0% | $10.96 | $11.14 | $10.81 | 6,301 | |
| $11.05 | -0.545 | -4.7% | $11.59 | $11.59 | $11.00 | 7,829 | |
| $11.59 | +0.465 | +4.2% | $10.98 | $12.33 | $10.72 | 24,575 | |
| $11.13 | -0.28 | -2.5% | $11.00 | $11.55 | $11.00 | 3,740 | |
| $11.41 | +0.145 | +1.3% | $12.00 | $12.00 | $10.81 | 22,019 | |
| $11.26 | +0.51 | +4.7% | $10.67 | $12.30 | $10.67 | 70,083 | |
| $10.75 | +1.747 | +19.4% | $9.46 | $10.86 | $9.44 | 45,929 | |
| $9.003 | +0.393 | +4.6% | $8.65 | $9.003 | $8.64 | 8,189 | |
| $8.61 | +0.03 | +0.3% | $8.90 | $8.90 | $8.60 | 3,212 | |
| $8.58 | -0.377 | -4.2% | $8.968 | $8.968 | $8.54 | 5,284 | |
| $8.957 | +0.232 | +2.7% | $9.01 | $9.04 | $8.38 | 15,885 | |
| $8.725 | +0.005 | +0.1% | $8.93 | $9.37 | $8.725 | 16,200 | |
| $8.72 | -0.48 | -5.2% | $9.27 | $9.27 | $8.72 | 3,300 | |
| $9.20 | +0.05 | +0.5% | $9.242 | $9.294 | $9.20 | 7,000 | |
| $9.15 | -0.535 | -5.5% | $9.99 | $10.09 | $9.145 | 15,900 | |
| $9.685 | -0.315 | -3.1% | $9.70 | $10.37 | $9.49 | 26,500 | |
| $10.00 | -0.01 | -0.1% | $10.00 | $10.00 | $9.00 | 19,400 | |
| $10.01 | -0.40 | -3.8% | $10.31 | $10.68 | $9.80 | 73,300 | |
| $10.41 | +0.67 | +6.9% | $10.09 | $11.58 | $9.54 | 90,200 | |
| $9.74 | +0.69 | +7.6% | $9.16 | $10.00 | $8.00 | 47,000 | |
| $9.05 | +0.062 | +0.7% | $9.05 | $9.14 | $8.76 | 6,400 | |
| $8.988 | +0.118 | +1.3% | $8.67 | $9.51 | $8.22 | 40,100 | |
| $8.87 | -0.28 | -3.1% | $9.31 | $9.31 | $8.70 | 10,300 | |
| $9.15 | -0.52 | -5.4% | $9.275 | $9.275 | $9.00 | 5,100 | |
| $9.67 | +0.41 | +4.4% | $9.50 | $9.67 | $9.26 | 6,200 | |
| $9.26 | -0.35 | -3.6% | $9.48 | $9.88 | $9.129 | 17,000 | |
| $9.61 | -0.71 | -6.9% | $10.56 | $10.87 | $9.15 | 56,500 | |
| $10.32 | -0.463 | -4.3% | $10.30 | $10.48 | $10.17 | 2,000 | |
| $10.78 | +0.293 | +2.8% | $10.39 | $10.87 | $10.08 | 13,500 | |
| $10.49 | +0.13 | +1.3% | $10.61 | $11.00 | $10.36 | 8,700 | |
| $10.36 | -0.415 | -3.9% | $10.50 | $10.76 | $10.36 | 4,500 | |
| $10.78 | +0.265 | +2.5% | $10.50 | $10.78 | $10.50 | 1,000 | |
| $10.51 | -0.65 | -5.8% | $10.93 | $11.35 | $10.50 | 13,400 | |
| $11.16 | +0.50 | +4.7% | $10.62 | $11.99 | $10.09 | 40,100 | |
| $10.66 | -0.24 | -2.2% | $11.03 | $11.03 | $10.50 | 6,500 | |
| $10.90 | -0.09 | -0.8% | $11.00 | $11.00 | $10.55 | 14,800 | |
| $10.99 | -0.04 | -0.4% | $11.01 | $11.07 | $10.36 | 32,000 | |
| $11.03 | +0.38 | +3.6% | $11.60 | $11.60 | $9.15 | 159,400 | |
| $10.65 | -0.74 | -6.5% | $11.31 | $11.80 | $10.61 | 12,100 | |
| $11.39 | +0.07 | +0.6% | $11.10 | $11.39 | $10.96 | 2,100 | |
| $11.32 | +0.29 | +2.6% | $10.99 | $11.53 | $10.63 | 69,300 | |
| $11.03 | -0.20 | -1.8% | $11.19 | $11.36 | $10.50 | 76,600 | |
| $11.23 | +0.48 | +4.5% | $10.65 | $11.28 | $10.42 | 43,800 | |
| $10.75 | -0.40 | -3.6% | $11.25 | $11.25 | $10.32 | 75,400 | |
| $11.15 | -0.09 | -0.8% | $11.08 | $11.85 | $10.99 | 164,200 | |
| $11.24 | -1.32 | -10.5% | $12.40 | $12.72 | $11.00 | 141,300 | |
| $12.56 | +0.05 | +0.4% | $12.00 | $13.28 | $11.95 | 134,400 | |
| $12.51 | -1.85 | -12.9% | $14.08 | $14.96 | $12.51 | 133,700 | |
| $14.36 | -0.15 | -1.0% | $14.32 | $15.34 | $13.71 | 276,200 | |
| $14.51 | +1.365 | +10.4% | $13.00 | $14.90 | $13.00 | 45,000 | |
| $13.15 | +0.345 | +2.7% | $12.70 | $13.29 | $12.22 | 96,400 | |
| $12.80 | +1.14 | +9.8% | $11.53 | $12.99 | $11.37 | 24,000 | |
| $11.66 | +0.76 | +7.0% | $10.89 | $11.84 | $10.89 | 41,700 | |
| $10.90 | +0.20 | +1.9% | $10.47 | $11.04 | $10.22 | 42,740 | |
| $10.70 | +0.40 | +3.9% | $10.75 | $10.75 | $9.70 | 39,309 | |
| $10.30 | -0.19 | -1.8% | $10.86 | $10.86 | $10.25 | 23,200 | |
| $10.49 | -0.70 | -6.3% | $11.50 | $12.00 | $10.26 | 100,900 |
Splits
2 splits since 2025 · NASDAQ:PLRZ · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-6 | Consolidation | |
| 1-for-250 | Consolidation |
- Ticker
- NASDAQ:PLRZ
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Polyrizon adopts limited duration shareholder rights plan
Latest news
Polyrizon adopts limited duration shareholder rights plan
Nov 9, 2026
Closed $10.93 (-1.1%) on Nov 10, 2026
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
Oct 27, 2026
Closed $8.58 (-4.2%) on Oct 27, 2026
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
Oct 5, 2026
Closed $9.26 (-3.6%) on Oct 5, 2026
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
Sep 22, 2026
Closed $10.66 (-2.2%) on Sep 22, 2026
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
Sep 4, 2026
Closed $11.24 (-10.5%) on Sep 4, 2026
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
Sep 3, 2026
Closed $12.56 (+0.4%) on Sep 3, 2026
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
Sep 2, 2026
Closed $12.51 (-12.9%) on Sep 2, 2026
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
Aug 20, 2026
Closed $10.49 (-6.3%) on Aug 20, 2026
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Jul 2, 2026
Closed $13.80 (+8.8%) on Jul 2, 2026
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
Jun 29, 2026
Closed $12.75 (+11.1%) on Jun 29, 2026
Polyrizon Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 42 in the last 12 months · 71 in all · newest Nov 9, 2026 · oldest 2024
Where Polyrizon Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PLRZ · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PLRZ | BOATS | United States | USD |
Valuation
Price/book 0.9× against a median of 1.2×: 4th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $7.56M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.67
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Polyrizon Ltd. · NASDAQ:PLRZ | US$22.61M | US$7.56M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.67 |
| Organoidsciences Ltd. · KRX:476040 | US$23.47M | US$6.53M | n/a | 3.8× | n/a | 1.1× | −814.8% | 0.4× | n/a |
| Immutep Ltd · ASX:IMM | US$23.44M | −US$24.95M | n/a | −2.6× | n/a | 0.6× | −544.8% | 0.0× | n/a |
| ABVC BioPharma, Inc. · NASDAQ:ABVC | US$23.37M | US$25.81M | n/a | n/a | n/a | 1.8× | n/a | 0.2× | 1.39 |
| Incannex Healthcare Inc. · NASDAQ:IXHL | US$23.33M | −US$44.85M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.98 |
| Actinogen Medical Limited · ASX:ACW | US$23.10M | US$15.18M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| BioNxt Solutions Inc · CSE:BNXT | US$22.78M | US$22.73M | n/a | n/a | n/a | n/a | n/a | n/a | 0.22 |
| ME Therapeutics Holdings, Inc. · CSE:METX | US$22.25M | US$21.88M | n/a | n/a | n/a | 49.5× | n/a | 0.0× | 0.52 |
| CervoMed Inc. · NASDAQ:CRVO | US$22.09M | US$2.49M | n/a | 285× | n/a | 1.3× | n/a | 0.0× | 1.97 |
| Sona Nanotech, Inc. · CSE:SONA | US$21.84M | US$22.07M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Mendus AB · OMXSTO:IMMU | US$21.79M | US$17.67M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | n/a |
| Median of the others | US$22.94M | US$16.43M | 3.8× | 1.2× | −679.8% | 0.0× | 0.75 |
Team and board
Officers
| Officer | Role |
|---|---|
| Tomer Izraeli | FOUNDER & CHIEF EXECUTIVE OFFICER |
| Nir Ben Yosef | CHIEF FINANCIAL OFFICER |
| Daphna Avital | CHIEF PEOPLE OFFICER |
| Eyal S. Ron | CHIEF SCIENTIFIC OFFICER |
| Tidhar Turgeman | CHIEF TECHNOLOGY OFFICER |
Board
| Director | Role |
|---|---|
| Asaf Itzhaik | Director |
| Liat Sidi | Director |
| Oz Adler | Director |
| Yehonatan Zalman Vinokur | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 17, 2025 | −6.3% |
| Q4 2024 | Mar 11, 2025 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of ordinary shares and pre-funded warrants Closed: US$12 a share · Aegis Capital Corp. Dealers: Aegis Capital Corp. (lead) Use of proceeds: General corporate purposes and working capital | Sep 4, 2026 |
| Private placement of pIPE pre-funded warrants and common warrants Closed: Warrants at US$12 · Aegis Capital Corp. Dealers: Aegis Capital Corp. (lead) Use of proceeds: General corporate purposes and working capital | Sep 4, 2026 |
| Private placement of ordinary Units (or Pre-Funded Units) Closed: US$17M raised · US$0.48 a unit · Warrants at US$1.2 for 30 months · Aegis Capital Corp. Dealers: Aegis Capital Corp. (lead) Use of proceeds: General corporate purposes and working capital | Apr 1, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Withdrawn on Mar 28, 2024. Filed with the SEC to go public on Aug 10, 2022.
- Price
- US$4.38 a unit
- Units offered
- 958,903 units
- Offering size
- US$4.2 million
- Underwriters' option
- Up to 143,835 more units
- Listing
- PLRZ on the Nasdaq Capital Market
- Underwriter
- Aegis Capital Corp.
- Units delivered
- On or about Oct 30, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 10, 2022 |
| Filed publicly | Aug 10, 2022 |
| Amended 12 times | Newest Oct 2, 2024 |
| Filing withdrawn | Mar 28, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 30, 2024 |
| 424B4 · Prospectus | Oct 30, 2024 |
| EFFECT · Notice that a registration is effective | Oct 28, 2024 |
| CERT · Exchange's certificate of listing | Oct 28, 2024 |
| CORRESP · Letter to the SEC | Oct 25, 2024 |
| CORRESP · Letter to the SEC | Oct 25, 2024 |
| CORRESP · Letter to the SEC | Oct 25, 2024 |
| CORRESP · Letter to the SEC | Oct 25, 2024 |
| CORRESP · Letter to the SEC | Oct 22, 2024 |
| CORRESP · Letter to the SEC | Oct 22, 2024 |
All 66 filings
Open IPO · From the cover of the final prospectus (424B4) filed Oct 30, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | ||
| Cost of revenue | 342.0K | 118.0K | 4.00K | 5.00K | 6.00K | 1.00K |
| Gross profit | -342.0K | -118.0K | -4.00K | -5.00K | -6.00K | -1.00K |
| Research and development | 2.13M | 534.0K | 332.0K | 347.0K | 245.0K | 38.0K |
| Selling, general and administrative | 3.65M | 768.0K | 303.0K | 533.0K | 452.0K | 33.0K |
| Operating income | -6.25M | -1.30M | -635.0K | -895.0K | -703.0K | -72.0K |
| Depreciation and amortization | 342.0K | 118.0K | 4.00K | 5.00K | 6.00K | 1.00K |
| EBITDA | -5.91M | -1.18M | -631.0K | -890.0K | -697.0K | -71.0K |
| Interest expense | 3.14M | 3.00K | 2.00K | 2.00K | 2.00K | |
| Income before tax | -3.33M | -1.54M | -600.0K | -779.0K | -711.0K | -73.0K |
| Net income | -3.33M | -1.54M | -600.0K | -779.0K | -711.0K | -73.0K |
| Earnings per share, basic | 4.90 | 805.20 | 494.40 | 0.60 | -0.17 | -0.02 |
| Earnings per share, diluted | 4.90 | 805.20 | 494.40 | 0.60 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 1.31M | 2.55M | 4.00K | 36.0K | 523.0K | 10.0K |
| Short-term investments | 11.0M | 0 | 37.0K | 0 | ||
| Current assets | 12.9M | 2.65M | 54.0K | 51.0K | 544.0K | 19.0K |
| Property, plant and equipment | 12.0K | 10.0K | 12.0K | |||
| Total assets | 21.4M | 5.55M | 559.0K | 546.0K | 687.0K | 24.0K |
| Current liabilities | 443.0K | 261.0K | 502.0K | 1.20M | 690.0K | 8.00K |
| Total debt | 200.0K | 622.0K | ||||
| Total liabilities | 443.0K | 261.0K | 750.0K | 1.20M | 690.0K | 8.00K |
| Shareholders' equity | 21.0M | 5.29M | -191.0K | -900.0K | -3.00K | 16.0K |
| Shares outstanding | 1.61M | 2.80K | 2.55M | 1.61M | 4.19M | 4.19M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -4.53M | -1.15M | -537.0K | -1.13M | -492.0K | -73.0K |
| Capital spending | -7.00K | 0 | 0 | -3.00K | -19.0K | -6.00K |
| Free cash flow | -4.54M | -1.15M | -537.0K | -1.14M | -511.0K | -79.0K |
| Cash from investing | -16.5M | 29.0K | -3.00K | -19.0K | -6.00K | |
| Cash from financing | 19.8M | 3.67M | 505.0K | 648.0K | 1.02M | 89.0K |
| Change in cash | -1.25M | 2.55M | -32.0K | -487.0K | 513.0K | 10.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Nov 9, 2026 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 27, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Oct 7, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 5, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 2, 2026 | Other filings | SEC |
| F-1/A · Registration statement, amended | Sep 28, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 28, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 201 filings. Open Filings
Cap table
Built by 6ix from Polyrizon Ltd.’s releases · as of Sep 4, 2026
- Common shares
- 2,428,604
- Fully diluted
- 37,845,271
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 2,428,604 | |
| Warrants | 35,416,667 | Apr 1, 2025 |
Warrants and options
| Lot |
|---|
| Warrants · US$12.00 · expiry not stated |
| Warrants · US$1.20 · expire about Oct 2027 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,428,604 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Oz Adler Other companies: Wearable Devices Ltd. (Director · Since at least Aug 13, 2026); Nexera Technologies Ltd (Director · Since at least Mar 18, 2026); Rail Vision Ltd. (Director · Since at least Mar 18, 2026); SciSparc Ltd. (Chief Executive Officer and Chief Financial Officer · Since at least Mar 18, 2026); Clearmind Medicine Inc. (Director · Since at least Mar 19, 2025) | Director · Since at least Mar 18, 2026 |
| Asaf Itzhaik Other companies: Clearmind Medicine Inc. (Director · Since at least Nov 5, 2026); Nexentis Technologies Inc. (Director · Since at least Dec 20, 2023) | Director · Since at least Mar 18, 2026 |
| Liat Sidi Other companies: SciSparc Ltd. (Director · Since at least Oct 23, 2025); Nexentis Technologies Inc. (Director · Since at least Nov 12, 2023) | Director · Since at least Mar 18, 2026 |
| Liron Carmel Other companies: Nexera Technologies Ltd (Director · Since at least Mar 18, 2026); Quantum X Labs Inc. (Director · Sep 19, 2022 – Sep 19, 2022 · Past) | Director · Since at least Mar 18, 2026 |
| Eyal S. Ron | Chief Science Officer · Since at least Mar 18, 2026 |
| Nir BenYosef | Chief Financial Officer · Since at least Mar 18, 2026 |
| Tidhar Turgeman | CHIEF TECHNOLOGY OFFICER · Since at least Mar 18, 2026 |
| Tomer Izraeli | FOUNDER & CHIEF EXECUTIVE OFFICER · Since at least Mar 18, 2026 |
| Yehonatan Zalman Vinokur | Director · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about Polyrizon Ltd.